An observational study in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 266 sites in 20 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. · Observational
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
173 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 37 are open to participants now.
This study's enrollment of 3,409 is above the median of 150 across 43 observational studies indexed under Polycystic Kidney, Autosomal Dominant.
Browse Polycystic Kidney, Autosomal Dominant studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 289 studies on the registry; 18 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 69 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects will be identified by participating clinics (primarily nephrology clinics) treating patients with ADPKD.
Exclusion Criteria:
Correlation of change in total kidney volume with ADPKD-related outcomes
Time frame: 1 year
Patient-reported pain
Time frame: every 6 months
SF-12 Scores
Time frame: every 6 months
ADPKD-Impact Scale Score
Time frame: every 6 months
Cost of care
Time frame: every 6 months
EQ-5D Scores
Time frame: Every 6 months
Showing the first 100 of 266 sites across 20 countries.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant→
Otsuka Pharmaceutical Development & Commercialization, Inc.